Cervical cancer: radiotherapy and hyperthermia
/in Cervical Cancer, International Publications /von 2006-05-01 / Int J Hyperthermia 2006 May;22(3):229-34HPV16/18 E7-pulsed dendritic cell vaccination in cervical cancer patients with recurrent disease refractory to standard treatment modalities
/in Cervical Cancer, Dendritic Cells, International Publications /von 2005-10-24 / Gynecol Oncol 2006 Mar;100(3):469-78First results of triple-modality treatment combining radiotherapy, chemotherapy, and hyperthermia for the treatment of patients with stage IIB, III, and IVA cervical carcinoma
/in Cervical Cancer, International Publications /von 2005-08-15 / Cancer 2005 Aug;104(4):763-70Human papillomavirus L1L2-E7 virus-like particles partially mature human dendritic cells and elicit E7-specific T-helper responses from patients with cervical intraepithelial neoplasia or cervical cancer in vitro
/in Cervical Cancer, International Publications /von 2005-07-01 / Hum. Immunol. 2005 Jul;66(7):762-72Editorial: clinical hyperthermia combined with radiation is safe
/in Cervical Cancer, International Publications /von 2005-05-01 / Int J Hyperthermia 2005 May;21(3):193-7Therapeutic vaccines for cervical cancer: dendritic cell-based immunotherapy
/in Cervical Cancer, Dendritic Cells, International Publications /von 2005-01-01 / Curr. Pharm. Des. 2005;11(27):3485-500Phase II study of carboplatin and whole body hyperthermia (WBH) in recurrent and metastatic cervical cancer
/in Cervical Cancer, International Publications /von 2004-12-01 / Gynecol. Oncol. 2004 Dec;95(3):680-5Dendritic cell-based vaccines in breast and gynaecologic cancer
/in Breast Cancer, Cervical Cancer, Dendritic Cells, International Publications, Ovarian Cancer /von 2003-09-01 / Anticancer Res. 2003 Sep-Oct;23(5b):4293-303Dendritic cell-based tumor vaccine for cervical cancer II: results of a clinical pilot study in 15 individual patients
/in Cervical Cancer, Dendritic Cells, International Publications /von 2003-07-30 / J. Cancer Res. Clin. Oncol. 2003 Sep;129(9):521-30IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de